123Indexed trials
Market Rank #25 · Evidence Tier A
Czechia
Neuroscience Intelligence
Czechia neuroscience intelligence: 123 indexed trials, 39 institutions, research score 36.15.
31Recruiting
39Research institutions
36.1Research score
Evidence profile
74Sponsors
22Disease areas
0Institution works
0Institution citations
Evidence signals
Research score 36.1 · Data confidence 100.00 · Evidence 36.1
Data confidence measures presence of evidence layers, not a probability of success. Scores are comparative decision-support signals, not guaranteed market size or commercial outcomes.
Leading disease areas
parkinsons23trials
epilepsy22trials
multiple_sclerosis14trials
alzheimers14trials
other_neurology10trials
pain_neuropathy6trials
stroke5trials
migraine_headache5trials
schizophrenia4trials
depression3trials
Leading indexed sponsors
Merck Sharp & Dohme LLC9trials
UCB Pharma6trials
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.6trials
Boehringer Ingelheim5trials
Masaryk University5trials
Ipsen4trials
Eisai Limited3trials
Biogen3trials
Genzyme, a Sanofi Company3trials
Amgen2trials